

# COMPANY UPDATE

2026. 8. 27

Innovation Team

Keunhee Seo, Ph.D.  
Team Leader  
keunhee.seo@samsung.com

Suhan Shin  
Research Associate  
shn.shin@samsung.com

▶ AT A GLANCE

| BUY                              |                       |       |
|----------------------------------|-----------------------|-------|
| Target price                     | KRW140,000            | 52.8% |
| Current price                    | KRW91,600             |       |
| Market cap                       | KRW7.2t/USD5.2b       |       |
| Shares (float)                   | 78,313,250 (49.8%)    |       |
| 52-week high/low                 | KRW140,700/KRW74,600  |       |
| Avg daily trading value (60-day) | KRW15.9b/<br>USD11.5m |       |

▶ ONE-YEAR PERFORMANCE

|                           | 1M   | 6M    | 12M   |
|---------------------------|------|-------|-------|
| SK Biopharmaceuticals (%) | 13.6 | -22.2 | -8.9  |
| Vs Kospi (%pts)           | 11.7 | -27.9 | -57.5 |

▶ KEY CHANGES

| (KRW)        | New     | Old     | Diff   |
|--------------|---------|---------|--------|
| Recommend.   | BUY     | BUY     |        |
| Target price | 140,000 | 130,000 | 7.7%   |
| 2026E EPS    | 3,889   | 4,480   | -13.2% |
| 2027E EPS    | 5,564   | 5,925   | -6.1%  |

▶ SAMSUNG vs THE STREET

|                                           |         |
|-------------------------------------------|---------|
| No of estimates                           | 13      |
| Target price                              | 138,846 |
| Recommendation                            | 4.0     |
| ※ Rating: 4 < → BUY, 3 = HOLD, 2 > → SELL |         |



Scan to go to  
Research Center report database

## SK Biopharmaceuticals (326030)

### Expands epilepsy portfolio

**Maintaining BUY; raising target price to KRW140,000:** By reducing its single-product dependency and diversifying its growth drivers, the signing of an exclusive licensing agreement for opakalim justifies SK Biopharmaceuticals' trading at a greater valuation premium in our view.

WHAT'S THE STORY?

**Enters global licensing agreement for opakalim:** SK Biopharmaceuticals has secured an exclusive global licensing agreement with Biohaven (US) for Kv7 activator compound (including opakalim, a lead candidate for epilepsy) and the full Kv7 discovery platform, it was disclosed on Aug 26. The deal is worth up to USD795m (USD400m upfront, USD395m in milestones, and ongoing royalties). Funding should be supported by existing cash reserves and debt financing. Upfront payments and milestones should be recognized as intangible assets and amortized linearly from 2029. R&D expenses tied to clinical progress should be recognized at USD20m per quarter through 2027. Opakalim is currently in Phase II/III trials for partial-onset seizures, with RISE2 results expected in 4Q26 and RISE3 results in 1Q28. Combined data from both trials should support an NDA submission in 2028 and a potential market launch in 1H29. Opakalim operates via Kv7 channel activation, a mechanism shared by next-generation antiepileptic agents that pose a competitive threat to SK Biopharmaceuticals' Xcopri. Notably, Xenon Pharmaceuticals' (US) azetukalner (XEN1101), which shares the same mechanism as opakalim, demonstrated superior seizure reduction and the convenience of no titration requirement in its Phase-III trial (X-TOLE2; completed in Mar 2026).

(Continued on the next page)

SUMMARY FINANCIAL DATA

|                          | 2025  | 2026E | 2027E | 2028E  |
|--------------------------|-------|-------|-------|--------|
| Revenue (KRWb)           | 707   | 989   | 1,270 | 1,808  |
| Operating profit (KRWb)  | 204   | 324   | 522   | 991    |
| Net profit (adj) (KRWb)  | 253   | 302   | 436   | 826    |
| EPS (adj) (KRW)          | 3,409 | 3,889 | 5,564 | 10,546 |
| EPS (adj) growth (% y-y) | 10.9  | 14.1  | 43.1  | 89.5   |
| EBITDA margin (%)        | 31.3  | 35.6  | 44.0  | 56.7   |
| ROE (%)                  | 39.3  | 31.3  | 32.2  | 41.6   |
| P/E (adj) (x)            | 36.6  | 23.6  | 16.5  | 8.7    |
| P/B (x)                  | 12.0  | 6.3   | 4.6   | 3.0    |
| EV/EBITDA (x)            | 43.1  | 20.4  | 12.2  | 5.9    |
| Dividend yield (%)       | 0.0   | 0.0   | 0.0   | 0.0    |

Source: Company data, Samsung Securities estimates

**To mitigate structural risk from single-product dependency:** SK Biopharmaceuticals' heavy reliance on Xcopri—whose patent expires in 2032—has raised concerns over future revenue erosion due to the looming penetration of generic products. This risk has been compounded by competitive pressure from new entrants such as Xenon Pharmaceuticals and Biohaven, which firms are advancing Kv7-activating agents, thereby capping valuation upside for SK Biopharmaceuticals. The recent opakalim licensing deal represents a positive step in lifecycle management. Opakalim, a next-generation agent with the same antiepileptic indication as Xcopri, offers improved safety and dosing convenience (vs Xcopri). It is positioned to leverage Xcopri's established prescription base, sales infrastructure, and physician relationships—not through cannibalization, but through a generational transition. While Xcopri targets patients with severe, refractory epilepsy through its strong efficacy—achieving a 20% rate of seizure freedom—opakalim could be targeted designed for milder, early-stage patients, benefiting from a low titration burden. This should enable a segmented, complementary market strategy.

**Maintaining BUY; raising target price to KRW140,000:** We adjust our valuation method for SK Biopharmaceuticals from a DCF to a SOTP model. Previously, a DCF model was used given the high-growth trajectory of Xcopri as a single product. However, with sales now firmly on track and cash flows entering a stable phase, we newly apply an EV/EBITDA multiple of 15.6x (a 30% premium to the pharmaceutical industry average of 12x, as per FnGuide) to our 2027 EBITDA estimate of KRW558.4b to derive an operating value of KRW8.71t. We estimate the company's new drug (opakalim) value at KRW1.79t using rNPV, incorporating an 80% probability of success and adjusting for annual R&D costs and future cash flows. This reflects the remaining development risk associated with opakalim, which drug: 1) the firm recently licensed; but 2) is still in Phase II/III trials (not yet commercialized). We believe this tailored, asset-specific valuation methodology provides a more reliable method of valuing the firm (vs a single DCF model). Although the first upfront payment (KRW472.5b) in 2026 should cause a temporary decline in SK Biopharmaceuticals' net cash holdings, we expect its net cash to recover to KRW346.5b by end-2027, supported by stable operating cash flows from Xcopri and despite a second milestone payment (of KRW67.5b in 2027).

### 3Q preview

| (KRWb)             | 3Q26E | 2Q26  | 3Q25  | Consensus | Diff (%) |       |           |
|--------------------|-------|-------|-------|-----------|----------|-------|-----------|
|                    |       |       |       |           | q-q      | y-y   | Consensus |
| Sales              | 255.7 | 247.4 | 191.7 | 252.3     | 3.4      | 33.4  | 1.3       |
| Operating profit   | 81.1  | 97.1  | 70.1  | 92.8      | (16.4)   | 15.8  | (12.6)    |
| Pre-tax profit     | 86.9  | 93.4  | 62.1  | 104.6     | (6.9)    | 40.0  | (16.8)    |
| Net profit         | 67.8  | 85.1  | 74.1  | 71.4      | (20.3)   | (8.5) | (5.0)     |
| <b>Margins (%)</b> |       |       |       |           |          |       |           |
| Operating profit   | 31.7  | 39.2  | 36.6  | 36.8      |          |       |           |
| Pre-tax profit     | 34.0  | 37.7  | 32.4  | 41.4      |          |       |           |
| Net profit         | 26.5  | 34.4  | 38.7  | 28.3      |          |       |           |

Source: Company data, FnGuide, Samsung Securities estimates

### SK Biopharmaceuticals: Target price calculation

| (KRWb)                                     | Calculation | Estimated value | 2027E | EV/EBITDA (x) |
|--------------------------------------------|-------------|-----------------|-------|---------------|
| Operating value (A)                        | (A)         | 8,710           | 558.4 | 15.6*         |
| New drug value (B)                         | (B)         | 1,785           |       |               |
| 2027E Net Cash                             | (C)         | 346             |       |               |
| Total Value                                | (D=A+B+C)   | 10,842          |       |               |
| Number of common shares outstanding ('000) | (E)         | 78,313          |       |               |
| Fair Stock Price (KRW)                     | (D/E)       | 138,444         |       |               |
| Target Price (KRW)                         |             | 140,000         |       |               |

Note: \* A 30% premium is applied to the average EV/EBITDA multiple of 12x for large pharmaceutical companies within our coverage, reflecting Xcopri's growth potential and the mitigation of prescription decline risks.

Source: FnGuide, Samsung Securities estimates

## Results and forecasts

| (KRWb)                   | 2025       | 2026E      | 2027E        | 1Q25       | 2Q25       | 3Q25       | 4Q25       | 1Q26       | 2Q26       | 3Q26E      | 4Q26E      | 1Q27E      | 2Q27E      | 3Q27E      | 4Q27E      |
|--------------------------|------------|------------|--------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| <b>Sales</b>             | <b>707</b> | <b>989</b> | <b>1,270</b> | <b>144</b> | <b>176</b> | <b>192</b> | <b>194</b> | <b>228</b> | <b>247</b> | <b>256</b> | <b>258</b> | <b>293</b> | <b>306</b> | <b>329</b> | <b>342</b> |
| Chg (% y-y)              | 29.1       | 40.0       | 28.4         | 26.7       | 31.6       | 40.4       | 19.2       | 57.8       | 40.3       | 33.4       | 32.9       | 28.7       | 23.7       | 28.7       | 32.3       |
| <b>Xcopri</b>            | <b>654</b> | <b>928</b> | <b>1,130</b> | <b>141</b> | <b>158</b> | <b>174</b> | <b>182</b> | <b>211</b> | <b>238</b> | <b>239</b> | <b>241</b> | <b>261</b> | <b>272</b> | <b>293</b> | <b>304</b> |
| US API                   | 630        | 873        | 1,011        | 133        | 154        | 172        | 171        | 198        | 224        | 227        | 224        | 233        | 243        | 263        | 273        |
| Europe DP                | 24         | 50         | 37           | 7          | 4          | 2          | 11         | 13         | 13         | 12         | 12         | 9          | 9          | 9          | 9          |
| Other                    | 0          | 0          | 59           | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 15         | 15         | 15         | 15         |
| Services*                | 53         | 62         | 85           | 4          | 18         | 18         | 13         | 17         | 10         | 17         | 18         | 18         | 20         | 22         | 24         |
| Europe DP                | 24         | 25         | 37           | 2          | 6          | 7          | 10         | 7          | 2          | 9          | 8          | 8          | 9          | 10         | 12         |
| Japan                    | 12         | 10         | 24           | 2          | 3          | 4          | 4          | 1          | 2          | 3          | 4          | 5          | 6          | 7          | 6          |
| Canada                   | 0          | 0          | 0            | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          |
| China                    | 5          | 0          | 0            | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          | 0          |
| Sunosi                   | 22         | 23         | 24           | 5          | 5          | 6          | 6          | 6          | 6          | 6          | 6          | 6          | 6          | 6          | 6          |
| Other                    | (0)        | (0)        | 55           | (0)        | (0)        | 0          | (0)        | (0)        | (0)        | 0          | (0)        | 14         | 14         | 14         | 14         |
| <b>COGS</b>              | <b>43</b>  | <b>61</b>  | <b>104</b>   | <b>10</b>  | <b>10</b>  | <b>8</b>   | <b>15</b>  | <b>14</b>  | <b>15</b>  | <b>14</b>  | <b>18</b>  | <b>24</b>  | <b>24</b>  | <b>26</b>  | <b>30</b>  |
| Chg (% y-y)              | (0.5)      | 42.2       | 71.1         | (12.1)     | 13.3       | (54.3)     | 154.4      | 36.5       | 51.6       | 80.1       | 20.8       | 64.0       | 62.9       | 93.9       | 66.3       |
| COGS-to-sales (%)        | 6.1        | 6.2        | 8.2          | 7.3        | 5.6        | 3.9        | 7.7        | 6.3        | 6.1        | 5.3        | 7.0        | 8.0        | 8.0        | 8.0        | 8.8        |
| <b>SG&amp;A expenses</b> | <b>460</b> | <b>604</b> | <b>644</b>   | <b>108</b> | <b>104</b> | <b>114</b> | <b>133</b> | <b>124</b> | <b>135</b> | <b>161</b> | <b>184</b> | <b>147</b> | <b>160</b> | <b>157</b> | <b>180</b> |
| Chg (% y-y)              | 12.7       | 31.3       | 6.6          | 18.0       | 5.3        | 13.3       | 14.3       | 14.4       | 29.5       | 41.1       | 38.2       | 19.0       | 17.9       | (2.6)      | (1.9)      |
| SG&A-to-sales (%)        | 65.1       | 61.1       | 50.7         | 74.9       | 59.3       | 59.5       | 68.5       | 54.3       | 54.7       | 62.9       | 71.2       | 50.2       | 52.2       | 47.6       | 52.8       |
| <b>Operating profit</b>  | <b>204</b> | <b>324</b> | <b>522</b>   | <b>26</b>  | <b>62</b>  | <b>70</b>  | <b>46</b>  | <b>90</b>  | <b>97</b>  | <b>81</b>  | <b>56</b>  | <b>122</b> | <b>122</b> | <b>146</b> | <b>131</b> |
| Chg (% y-y)              | 111.7      | 59.0       | 60.9         | 149.3      | 137.6      | 262.4      | 13.8       | 249.7      | 56.9       | 15.8       | 21.5       | 36.4       | 25.6       | 80.0       | 133.3      |
| Operating margin (%)     | 28.9       | 32.8       | 41.1         | 17.8       | 35.1       | 36.6       | 23.8       | 39.4       | 39.2       | 31.7       | 21.8       | 41.7       | 39.9       | 44.4       | 38.4       |
| <b>Pre-tax profit</b>    | <b>151</b> | <b>340</b> | <b>558</b>   | <b>20</b>  | <b>35</b>  | <b>62</b>  | <b>34</b>  | <b>100</b> | <b>93</b>  | <b>87</b>  | <b>60</b>  | <b>133</b> | <b>129</b> | <b>155</b> | <b>141</b> |
| Chg (% y-y)              | 107.8      | 125.3      | 64.2         | 162.1      | 45.7       | 553.8      | 7.0        | 391.6      | 169.2      | 40.0       | 76.8       | 33.1       | 38.7       | 78.2       | 136.7      |
| <b>Net profit</b>        | <b>267</b> | <b>305</b> | <b>436</b>   | <b>23</b>  | <b>33</b>  | <b>74</b>  | <b>137</b> | <b>105</b> | <b>85</b>  | <b>68</b>  | <b>47</b>  | <b>104</b> | <b>101</b> | <b>121</b> | <b>110</b> |
| Chg (% y-y)              | 10.9       | 14.1       | 43.0         | 81.6       | 17.0       | 667.9      | (28.2)     | 351.2      | 158.4      | (8.5)      | (65.9)     | (1.3)      | 18.7       | 78.2       | 136.7      |
| Net margin (%)           | 37.8       | 30.8       | 34.3         | 16.1       | 18.7       | 38.7       | 70.3       | 46.1       | 34.4       | 26.5       | 18.0       | 35.4       | 33.0       | 36.7       | 32.2       |

Notes: \*Upfront payment and milestone payment + Sunosi royalty estimates

Source: Company data, Samsung Securities estimates

## Income statement

| Year-end Dec 31 (KRWb)                 | 2024       | 2025       | 2026E      | 2027E        | 2028E        |
|----------------------------------------|------------|------------|------------|--------------|--------------|
| <b>Sales</b>                           | <b>548</b> | <b>707</b> | <b>989</b> | <b>1,270</b> | <b>1,808</b> |
| Cost of goods sold                     | 43         | 43         | 61         | 104          | 149          |
| <b>Gross profit</b>                    | <b>504</b> | <b>664</b> | <b>928</b> | <b>1,166</b> | <b>1,659</b> |
| Gross margin (%)                       | 92.1       | 93.9       | 93.8       | 91.8         | 91.8         |
| SG&A expenses                          | 408        | 460        | 604        | 644          | 668          |
| <b>Operating profit</b>                | <b>96</b>  | <b>204</b> | <b>324</b> | <b>522</b>   | <b>991</b>   |
| Operating margin (%)                   | 17.6       | 28.9       | 32.8       | 41.1         | 54.8         |
| <b>Non-operating gains (losses)</b>    | <b>-24</b> | <b>-53</b> | <b>16</b>  | <b>37</b>    | <b>68</b>    |
| Financial profit                       | 52         | 36         | 45         | 43           | 66           |
| Financial costs                        | 45         | 51         | 41         | 39           | 34           |
| Equity-method gains (losses)           | -31        | -34        | 14         | 33           | 36           |
| Other                                  | 1          | -4         | -2         | 0            | 0            |
| <b>Pre-tax profit</b>                  | <b>73</b>  | <b>151</b> | <b>340</b> | <b>559</b>   | <b>1,059</b> |
| Taxes                                  | -154       | -102       | 38         | 123          | 233          |
| Effective tax rate (%)                 | -212.7     | -67.8      | 11.1       | 22.0         | 22.0         |
| Profit from continuing operations      | 227        | 253        | 302        | 436          | 826          |
| Profit from discontinued operations    | 0          | 0          | 0          | 0            | 0            |
| <b>Net profit</b>                      | <b>227</b> | <b>253</b> | <b>302</b> | <b>436</b>   | <b>826</b>   |
| Net margin (%)                         | 41.4       | 35.8       | 30.5       | 34.3         | 45.7         |
| Net profit (controlling interests)     | 241        | 267        | 305        | 436          | 826          |
| Net profit (non-controlling interests) | -14        | -14        | -2         | 0            | 0            |
| EBITDA                                 | 114        | 221        | 352        | 558          | 1,025        |
| EBITDA margin (%)                      | 20.8       | 31.3       | 35.6       | 44.0         | 56.7         |
| EPS (parent-based) (KRW)               | 3,074      | 3,409      | 3,889      | 5,564        | 10,546       |
| EPS (consolidated) (KRW)               | 2,898      | 3,234      | 3,858      | 5,564        | 10,546       |
| Adjusted EPS (KRW)*                    | 3,074      | 3,409      | 3,889      | 5,564        | 10,546       |

## Cash flow statement

| Year-end Dec 31 (KRWb)                   | 2024       | 2025        | 2026E       | 2027E      | 2028E        |
|------------------------------------------|------------|-------------|-------------|------------|--------------|
| <b>Cash flow from operations</b>         | <b>95</b>  | <b>176</b>  | <b>206</b>  | <b>414</b> | <b>792</b>   |
| Net profit                               | 227        | 253         | 302         | 436        | 826          |
| Non-cash profit and expenses             | -88        | -21         | 78          | 134        | 218          |
| Depreciation                             | 11         | 13          | 11          | 5          | 2            |
| Amortization                             | 6          | 4           | 17          | 32         | 32           |
| Other                                    | -106       | -38         | 50          | 98         | 184          |
| Changes in A/L from operating activities | -33        | -36         | -134        | -20        | -23          |
| <b>Cash flow from investments</b>        | <b>-11</b> | <b>-35</b>  | <b>-487</b> | <b>-67</b> | <b>5</b>     |
| Change in tangible assets                | -1         | -7          | -2          | 0          | 0            |
| Change in financial assets               | -1         | -4          | -14         | -4         | -5           |
| Other                                    | -9         | -25         | -471        | -63        | 9            |
| <b>Cash flow from financing</b>          | <b>-4</b>  | <b>-157</b> | <b>190</b>  | <b>1</b>   | <b>1</b>     |
| Change in debt                           | 11         | -137        | 202         | 1          | 1            |
| Change in equity                         | 0          | 0           | 4           | 0          | 0            |
| Dividends                                | 0          | 0           | 0           | 0          | 0            |
| Other                                    | -15        | -20         | -16         | 0          | 0            |
| Change in cash                           | 83         | -15         | -81         | 372        | 823          |
| Cash at beginning of year                | 240        | 323         | 308         | 227        | 599          |
| Cash at end of year                      | 323        | 308         | 227         | 599        | 1,422        |
| <b>Gross cash flow</b>                   | <b>139</b> | <b>232</b>  | <b>380</b>  | <b>570</b> | <b>1,044</b> |
| <b>Free cash flow</b>                    | <b>94</b>  | <b>169</b>  | <b>204</b>  | <b>414</b> | <b>792</b>   |

Note: \*Excluding one-off items

\*\*Fully diluted, excluding one-off items

\*\*\*From companies subject to equity-method valuation

Source: Company data, Samsung Securities estimates

## Balance sheet

| Year-end Dec 31 (KRWb)                   | 2024         | 2025         | 2026E        | 2027E        | 2028E        |
|------------------------------------------|--------------|--------------|--------------|--------------|--------------|
| <b>Current assets</b>                    | <b>651</b>   | <b>683</b>   | <b>756</b>   | <b>1,194</b> | <b>2,091</b> |
| Cash & equivalents                       | 323          | 308          | 227          | 599          | 1,422        |
| Accounts receivable                      | 174          | 229          | 331          | 372          | 419          |
| Inventories                              | 112          | 100          | 102          | 115          | 129          |
| Other current assets                     | 43           | 46           | 96           | 108          | 122          |
| <b>Fixed assets</b>                      | <b>385</b>   | <b>515</b>   | <b>999</b>   | <b>1,043</b> | <b>1,023</b> |
| Investment assets                        | 98           | 75           | 104          | 117          | 132          |
| Tangible assets                          | 12           | 15           | 9            | 4            | 2            |
| Intangible assets                        | 33           | 51           | 513          | 548          | 516          |
| Other long-term assets                   | 243          | 374          | 373          | 373          | 373          |
| <b>Total assets</b>                      | <b>1,037</b> | <b>1,198</b> | <b>1,754</b> | <b>2,236</b> | <b>3,115</b> |
| <b>Current liabilities</b>               | <b>396</b>   | <b>295</b>   | <b>542</b>   | <b>584</b>   | <b>631</b>   |
| Accounts payable                         | 3            | 9            | 8            | 9            | 10           |
| Short-term debt                          | 0            | 0            | 200          | 200          | 200          |
| Other current liabilities                | 393          | 286          | 334          | 375          | 421          |
| <b>Long-term liabilities</b>             | <b>67</b>    | <b>77</b>    | <b>76</b>    | <b>80</b>    | <b>85</b>    |
| Bonds & long-term debt                   | 0            | 0            | 0            | 0            | 0            |
| Other long-term liabilities              | 67           | 77           | 76           | 80           | 85           |
| <b>Total liabilities</b>                 | <b>463</b>   | <b>372</b>   | <b>618</b>   | <b>665</b>   | <b>717</b>   |
| <b>Owners of parent equity</b>           | <b>546</b>   | <b>813</b>   | <b>1,136</b> | <b>1,572</b> | <b>2,398</b> |
| Capital stock                            | 39           | 39           | 39           | 39           | 39           |
| Capital surplus                          | 1,085        | 1,085        | 1,089        | 1,089        | 1,089        |
| Retained earnings                        | -622         | -354         | -50          | 386          | 1,212        |
| Other                                    | 44           | 43           | 57           | 57           | 57           |
| <b>Non-controlling interests' equity</b> | <b>28</b>    | <b>13</b>    | <b>0</b>     | <b>0</b>     | <b>0</b>     |
| <b>Total equity</b>                      | <b>574</b>   | <b>826</b>   | <b>1,136</b> | <b>1,572</b> | <b>2,398</b> |
| Net debt                                 | -136         | -257         | 25           | -346         | -1,169       |


## Financial ratios

| Year-end Dec 31             | 2024  | 2025   | 2026E  | 2027E  | 2028E  |
|-----------------------------|-------|--------|--------|--------|--------|
| <b>Growth (%)</b>           |       |        |        |        |        |
| Sales                       | 54.3  | 29.1   | 40.0   | 28.4   | 42.3   |
| Operating profit            | nm    | 111.7  | 59.0   | 60.9   | 90.0   |
| Net profit                  | nm    | 11.6   | 19.3   | 44.2   | 89.5   |
| Adjusted EPS**              | nm    | 10.9   | 14.1   | 43.1   | 89.5   |
| <b>Per-share data (KRW)</b> |       |        |        |        |        |
| EPS (parent-based)          | 3,074 | 3,409  | 3,889  | 5,564  | 10,546 |
| EPS (consolidated)          | 2,898 | 3,234  | 3,858  | 5,564  | 10,546 |
| Adjusted EPS**              | 3,074 | 3,409  | 3,889  | 5,564  | 10,546 |
| BVPS                        | 6,975 | 10,382 | 14,507 | 20,072 | 30,618 |
| DPS (common)                | 0     | 0      | 0      | 0      | 0      |
| <b>Valuations (x)</b>       |       |        |        |        |        |
| P/E***                      | 36.1  | 36.6   | 23.6   | 16.5   | 8.7    |
| P/B***                      | 15.9  | 12.0   | 6.3    | 4.6    | 3.0    |
| EV/EBITDA                   | 75.5  | 43.1   | 20.4   | 12.2   | 5.9    |
| <b>Ratios (%)</b>           |       |        |        |        |        |
| ROE                         | 58.0  | 39.3   | 31.3   | 32.2   | 41.6   |
| ROA                         | 25.8  | 22.7   | 20.5   | 21.8   | 30.9   |
| ROIC                        | 122.1 | 115.0  | 44.0   | 39.6   | 71.4   |
| Payout ratio                | 0.0   | 0.0    | 0.0    | 0.0    | 0.0    |
| Dividend yield (common)     | 0.0   | 0.0    | 0.0    | 0.0    | 0.0    |
| Net debt to equity          | -23.7 | -31.2  | 2.2    | -22.0  | -48.7  |
| Interest coverage (x)       | 9.0   | 26.5   | 26.8   | 21.9   | 41.4   |

## Compliance notice

- As of 8/26 2026, the covering analyst(s) did not own any shares, or debt instruments convertible into shares, of any company covered in this report.
- As of 8/26 2026, Samsung Securities' holdings of shares and debt instruments convertible into shares of each company covered in this report would not, if such debt instruments were converted, exceed 1% of each company's outstanding shares.
- This report has been prepared without any undue external influence or interference, and accurately reflects the views of the analyst(s) covering the company or companies herein.
- All material presented in this report, unless specifically indicated otherwise, is under copyright to Samsung Securities.
- Neither the material nor its content (including copies) may be altered in any form, or by any means transmitted, copied, or distributed to another party, without prior express written permission from Samsung Securities.
- This memorandum is based upon information available to the public. While we have taken all reasonable care to ensure its reliability, we do not guarantee its accuracy or completeness. This memorandum is not intended to be an offer, or a solicitation of any offer, to buy or sell the securities mentioned herein. Samsung Securities shall not be liable whatsoever for any loss, direct or consequential, arising from the use of this memorandum or its contents. Statements made regarding affiliates of Samsung Securities are also based upon publicly available information and do not necessarily represent the views of management at such affiliates.
- This material has not been distributed to institutional investors or other third parties prior to its publication.

## Target price changes in past two years



## Rating changes over past two years (adjusted share prices)

| Date               | 2024/9/9 | 11/11  | 2025/2/7 | 5/12   | 11/6   | 2026/8/6 | 8/27   |
|--------------------|----------|--------|----------|--------|--------|----------|--------|
| Recommendation     | BUY      | BUY    | BUY      | BUY    | BUY    | BUY      | BUY    |
| Target price (KRW) | 130000   | 140000 | 150000   | 130000 | 140000 | 130000   | 140000 |
| Gap* (average)     | -12.32   | -24.25 | -27.98   | -23.06 | -24.78 | -33.09   |        |
| (max or min)**     | -3.15    | -9.29  | -14.80   | -7.23  | 0.50   | -29.54   |        |

Note: \* [(average, maximum, or minimum share price over duration of target price minus target price) / target price] x 100%

\*\* Maximum/minimum share price if new target is higher/lower than market close on the business day prior to target price change

## Samsung Securities uses the following investment ratings\*

### Company

|             |                                                                                                      |
|-------------|------------------------------------------------------------------------------------------------------|
| <b>BUY</b>  | Expected to increase in value by 15% or more within 12 months and is highly attractive within sector |
| <b>HOLD</b> | Expected to increase/decrease in value by less than 15% within 12 months                             |
| <b>SELL</b> | Expected to decrease in value by 15% or more within 12 months                                        |

### Industry

|                    |                                                                             |
|--------------------|-----------------------------------------------------------------------------|
| <b>OVERWEIGHT</b>  | Expected to outperform market by 5% or more within 12 months                |
| <b>NEUTRAL</b>     | Expected to outperform/underperform market by less than 5% within 12 months |
| <b>UNDERWEIGHT</b> | Expected to underperform market by 5% or more within 12 months              |

\* Note: Effective Jul 27, 2023, BUY, HOLD, and SELL criteria are based on expectations of share-price moves of 15% or more within 12 months

## Percentage of ratings in 12 months prior to 2026.06.30

BUY (85.5%)-HOLD (14.5%)-SELL (0%)

## Global Disclosures & Disclaimers

### General

This research report is for information purposes only. It is not and should not be construed as an offer or solicitation of an offer to purchase or sell any securities or other financial instruments or to participate in any trading strategy. This report does not provide individually tailored investment advice. This report does not take into account individual client circumstances, objectives, or needs and is not intended as recommendations of particular securities, financial instruments or strategies to any particular client. The securities and other financial instruments discussed in this report may not be suitable for all investors. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein and investors should seek the advice of a financial adviser.

This report may not be altered, reproduced, distributed, transmitted or published in whole or in part for any purpose. References to "Samsung Securities" are references to any company in the Samsung Securities, Co., Ltd. group of companies.

Samsung Securities and/or other affiliated companies, its and their directors, officers, representatives, or employees may have long or short positions in any of the securities or other financial instruments mentioned in this report or of issuers described herein and may purchase and/or sell, or offer to purchase and/or sell, at any time, such securities or other financial instruments in the open market or otherwise, as either a principal or agent. Any pricing of securities or other financial instrument contained herein is as of the close of market for such day, unless otherwise stated. Opinions and estimates contained herein constitute our judgment as of the date of this report and are subject to change without notice.

The information provided in this report is provided "AS IS". Although the information contained herein has been obtained from sources believed to be reliable, no representation or warranty, either expressed or implied, is provided by Samsung Securities in relation to the accuracy, completeness or reliability of such information or that such information was provided for any particular purpose and Samsung Securities expressly disclaims any warranties of merchantability or fitness for a particular purpose. Furthermore, this report is not intended to be a complete statement or summary of the securities, markets or developments referred to herein.

Samsung Securities does not undertake that investors will obtain any profits, nor will it share with investors any investment profits. Samsung Securities, its affiliates, or any of its and their affiliates, directors, officers, employees or agents disclaim any and all responsibility or liability whatsoever for any loss (direct or consequential) or damage arising out of the use of all or any part of this report or its contents or otherwise arising in connection therewith. Information and opinions contained herein are subject to change without notice. Past performance is not indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of Samsung Securities. Any analysis contained herein is based on numerous assumptions. Different assumptions may result in materially different results. Samsung Securities is under no obligation to update or keep current the information contained herein. Samsung Securities relies on information barriers to control the flow of information contained in one or more areas or groups within Samsung Securities into other areas or groups of Samsung Securities. Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other financial instruments. Samsung Securities makes no representation that any transaction can or could have been effected at those prices and any prices contained herein may not reflect Samsung Securities' internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by Samsung Securities or any other source may yield substantially different results. Additional information is available upon request.

### For reports to be distributed to US:

Securities research is prepared, issued and exclusively distributed by Samsung Securities Co., Ltd., an organization licensed with the Financial Supervisory Service of South Korea. This research may be distributed in the United States only to major institutional investors as defined in Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended, and may not be circulated to any other person otherwise. All transactions by U.S. investors involving securities discussed in this report must be effected through Samsung Securities (America) Inc., a broker-dealer registered with the U.S. Securities & Exchange Commission and a member of the Financial Industry Regulatory Authority/SIPC, and not through any non-U.S. affiliate thereof. The analysts listed [on the front of this report] are employees of Samsung Securities Co., Ltd., or a non-U.S. affiliate thereof, and are not registered/qualified as research analysts under applicable U.S. rules and regulations and may not be subject to U.S. restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

### For reports to be distributed to UK:

This report is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000 of the United Kingdom ("FSMA"). To the extent that this report does constitute such an invitation or inducement, it is directed only at (i) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (as amended) of the United Kingdom (the "Financial Promotion Order"); (ii) persons who fall within Articles 49(2)(a) to (d) ("high-net-worth companies, unincorporated associations etc.") of the Financial Promotion Order; and (iii) any other persons to whom this report can, for the purposes of section 21 of FSMA, otherwise lawfully be made (all such persons together being referred to as "relevant persons").

Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons must not act or rely on this report.

### For reports to be distributed to Korea:

This report is for private circulation only, not for sale, and is issued and distributed only to persons permitted under the laws and regulations of Korea.

### For reports to be distributed to Singapore:

This report is provided pursuant to the financial advisory licensing exemption under Regulation 27(1)(e) of the Financial Advisers Regulation of Singapore and accordingly may only be provided to persons in Singapore who are "institutional investors" as defined in Section 4A of the Securities and Futures Act, Chapter 289 of Singapore. This report is intended only for the person to whom Samsung Securities has provided this report and such person may not send, forward or transmit in any way this report or any copy of this report to any other person.

### Analyst certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of such analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research report. The analyst(s) principally responsible for the preparation of this research report receives compensation based on determination by research management and senior management (not including investment banking), based on the overall revenues, including investment banking revenues of Samsung Securities Co., Ltd. and its related entities and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Copyright © 2010 Samsung Securities Co., Ltd. All rights reserved. This report or any portion hereof may not be reprinted, sold or redistributed without the prior written consent of Samsung Securities America Inc

## Samsung Securities

### SAMSUNG SECURITIES

Samsung Electronics Bldg., 11, 74-gil,  
Seochodae-ro, Seocho-gu, Seoul, Korea 06620  
Tel: 02 2020 8000 / [www.samsungpop.com](http://www.samsungpop.com)

**Family Center:** 1588 2323

**Voice Of Customer:** 080 911 0900

---

**For more information,  
please call our sales representatives:**

#### LONDON

##### Samsung Securities Europe Limited

1st Floor, 30 Gresham Street, London EC2V 7PG UK  
Tel. 44-207-776-4311  
Fax. 44-203-837-9219

#### NEW YORK

##### Samsung Securities America Limited

1330 Avenue of the Americas. 10th Floor. New York,  
NY 10019  
Tel: 1-212-972-2454  
Fax: 1-212-972-2704

#### HONG KONG

##### Samsung Securities (Asia) Limited

Suite 4511, Two International Finance Center,  
8 Finance Street, Central, Hong Kong  
Tel: 852-3411-3608  
Fax: 852-2114-0290

#### BEIJING

##### Samsung Securities Beijing Representative Office

Rm. 910, The Exchange Building No 118 JianGuo Lu, Chao  
Yang District, Beijing, China  
Tel: 86-10-6522-1855 (extension 7891)  
Fax: 86-10-6522-1855 (extension 7889)

#### TOKYO

##### Samsung Securities Tokyo Representative Office

#106-8532 19F, Roppongi T-Cube 3-1-1,  
Roppongi Minato-ku Tokyo, Japan  
Tel: 81-3-6333-2952  
Fax: 81-3-6333-2953

---



Member of  
**Dow Jones  
Sustainability Indices**  
Powered by the S&P Global CSA